Screener
Vertex Pharmaceuticals VRTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's EPS (diluted)?
- Vertex Pharmaceuticals (VRTX) reported EPS (diluted) of $4.31 in Q2 2026.
- How has Vertex Pharmaceuticals's EPS (diluted) changed year-over-year?
- Vertex Pharmaceuticals's EPS (diluted) increased by 8.0% year-over-year, from $3.99 to $4.31.
- What is the long-term trend for Vertex Pharmaceuticals's EPS (diluted)?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's EPS (diluted) has grown at a 19.4% compound annual growth rate (CAGR), from $9.01 to $15.32.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Vertex Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude